Introduction
Actin has been deeply studied and concluded as an evolutionary conserved molecule and one of the major cytoskeletal components in eukaryotic cells including tumor cells [1, 2] . Actin exists in two forms, the monomeric actin and microfilament that is a polymerized form of monomeric actin. Each microfilament has two different specific ends, at which polymerization happens at different rates, a fast growing or 'barbed' end and a slow-growing or 'pointed' end, which keep in a dynamic balance between monomeric and polymerized actins [2] [3] [4] . The polymerization, depolymerization and redistribution of actin microfilaments are delicately regulated by a variety of extracellular and intracellular factors [1, 5, 6] . At present, more and more study results have indicated that microfilaments are involved in various cellular functions including cell morphology, migration, ion channels activity, secretion, apoptosis and cell survival. Therefore, disruption of microfilaments by chemical agents, such as cytochalasins, can cause severe damages in cell function, even culminating in cell death or apoptosis [7] [8] [9] [10] .
Cytochalasins are a group of chemical agents, which are mainly isolated from symbiotic fungi in tropical countries and areas. Cytochalasins are capable of permeating cell membranes, binding to actin and altering its polymerization. At present, several lines of evidence have indicated that cytochalasin B and E possess somewhat anticancer activities [11, 12] . However, cytochalasin D (Cyt D) is thought to be the most specific for the actin microfilaments among various cytochalasins at present [13] . Functionally, Cyt D Objective: To investigate whether cytochalasin D can induce antitumor activities in a tumor model. Methods: Murine CT26 colorectal carcinoma cells were cultured in vitro and cytochalasin D was used as a cytotoxic agent to detect its capabilities of inhibiting CT26 cell proliferation and inducing cell apoptosis by MTT and a TUNEL-based apoptosis assay. Murine CT26 tumor model was established to observe the tumor growth and survival time. Tumor tissues were used to detect the microvessel density by immunohistochemistry. In addition, alginate encapsulated tumor cell assay was used to quantify the tumor angiogenesis in vivo. Results: Cytochalasin D inhibited CT26 tumor cell proliferation in time and dose dependent manner and induced significant CT26 cell apoptosis, which almost reached the level induced by the positive control nuclease. The optimum effective dose of cytochalasin D for in vivo therapy was about 50 mg/kg. Cytochalasin D in vivo treatment significantly inhibited tumor growth and prolonged the survival times in CT26 tumor-bearing mice. The results of immunohistochemistry analysis and alginate encapsulation assay indicated that the cytochalasin D could effectively inhibited tumor angiogenesis. Conclusions: Cytochalasin D inhibits CT26 tumor growth potentially through inhibition of cell proliferation, induction of cell apoptosis and suppression of tumor angiogenesis.
can specifically binds to the barbed end of growing actin microfilaments and at last causes inhibition or disruption of actin microfilaments by altering actin polymerization [2] . Therefore, it is reasonable to consider that Cyt D may be a candidate cytotoxic agent for tumor therapy. In this study, we used murine colorectal tumor cell line CT26 to investigate the possible Cyt D's anticancer activities. Our results showed that Cyt D can induce CT26 cell apoptosis and proliferation in vitro and suppressed tumor growth and angiogenesis in vivo, suggesting its therapeutic values in cancer treatment.
Materials and methods

Cell culture
Murine colorectal carcinoma cell line CT26 (CT26) was purchased from the American Type Culture Collection (ATCC, Manassas, VA). CT26 cells were cultured in RPMI1640 (Gibical) supplemented with 10% fetal bovine serum, 100 IU/mL penicillin and 100 mg/mL streptomycin at 37 曟 in a humidified atmosphere with 5% CO 2 . The logarithmic phase cells were used for subsequent experiments.
MTT assay
For MTT assay, CT26 cells in logarithmic growth were trypsinized and harvested, and then the cells were seeded onto a 96-well plate. After 24 h, fresh RPMI 1640 medium containing different concentrations of Cyt D (0.75, 1.25, 2.5, 5.0, 7.5, 10 and 15 毺 g/mL) was added at 100 毺 L per well respectively and each concentration has 6 replicate wells. After incubation for different time intervals, 10 毺 L of MTT (5 mg/mL) was added to each well and the cells were further incubated at 37 曟 for 4 hours. Then the supernatant was removed and 100 毺 L DMSO was added into each well. In the end, the absorbance (A value) at wavelength of 490 nm was measured with a microplate reader (Bio-Tek EXL808).
Detection of cell apoptosis in vitro
A TUNEL-based apoptosis detection was performed using TiterTACS In Situ Detection Kit (Trevigen) as described in previous study [14] . In brief, CT26 cells were seeded in 96-well plates and incubated for 16 h in the presence or absence of tested drugs at a concentration of the optimum dose decided from the above MTT results. Thereafter, cells were fixed and nick-end labeled as recommended by the manufacturer's protocol. The absorbance at 450 nm (A450 nm), corresponding to the amount of nickends, was normalized to the amount of cells, as evaluated from crystal violet staining (A540 nm). For purpose of clearly representation, all A450 nm/A540 nm signals were normalized to the signal obtained from unlabeled sample (cells treated with DMSO and without nick-end labeling) as negative control. For positive control, the nuclease-treated cells were treated with TACS Nuclease after fixation, and then nick-end labeled.
Establishment of tumor models
Female BALB/c mice at 6 to 8 weeks of age were used for establishment of tumor models. To established tumor model, BALB/c mice were injected s.c. with 2伊10 6 corresponding tumor cells in the dorsal area. The animal protocols in this study were approved by the College's Animal Care and Use Committee.
Determination of optimum effective dose
CT26-bearing BABL/c mice were randomly divided into six groups (n = 5 for each group). Treatment started when tumor volume was about 90 mm 3 . These mice were injected i.v. with various does of Cyt D (12.5, 25, 50 and 100 mg/kg in 200 毺 L DMSO) and DMSO (200 毺 L), respectively. All these reagents were given every 3 days for 15 days. The mice were sacrificed on day 18 , and tumor tissues were excised and weighed. The optimum effective dose of Cyt D for further experiments was decided according to the tumor weights.
In vivo observations of antitumor activities
Tumor-bearing mice injected with CT26 cells were divided into two groups (n = 10 for each group) and i.v. injected with Cyt D (50 mg/kg in 100 DMSO) and DMSO (100 毺 L, as negative control) very 3 days for 21 days, respectively. The tumor volumes and survival time were observed. Tumor volumes were calculated according to the formula: V = 0.52a 伊 b 2 , where a is the largest superficial diameter and b is the smallest superficial diameter. The mice were sacrificed when they became moribund and the sacrificed date was then recorded to calculate the survival time. In addition, tumor tissues were also excised, fixed in 10% formalin and frozen in -80 for detections of microvessel density.
Detection of microvessel density in tumor tissues
For microvessel density (MVD) analysis in tumor tissues, frozen sections were fixed in acetone, incubated, and stained with an antibody reactive to CD31 as we previously done [15] . The sections were then stained with labeled streptavidin biotin reagents (Dako LSAB kit, peroxidase; Dako). Vessel density was determined by counting the number of microvessels per high-power field (hpf) in the sections.
Alginate encapsulation assay
Alginate encapsulated tumor cell assays were performed as previously described [16] . Briefly, CT26 cells were resuspended in a 1.5% solution of sodium alginate and added dropwise into a swirling 37 曟 solution of 250 mM calcium chloride. Alginate beads were formed containing approximately 1伊10 5 tumor cells per bead. Experiment mice were then anesthetized, and four beads were implanted subcutaneously into an incision made on the dorsal side. Incisions were closed with surgical clamps. After 14 days, mice were injected intravenously with 100 毺 L of a 100 mg/kg FITC-dextran solution (Sigma). Beads were surgically removed and FITC-dextran quantified against a standard curve of FITC-dextran.
Statistical analysis
An unpaired Student's t-test was used to compare the statistical differences in the experimental values between two samples. Survival curves were constructed according to the Kaplan-Meier method and statistical significance was determined by the log-rank test. A P values < 0.05 was considered statistically significant. Error bars represent SEM unless otherwise indicated. Cell proliferation was detected by Proliferation ELISA kit. Data are expressed as means 依 SEM, *P < 0.01 or less, compared to the various dose or DMSO-treated CT26 cells.
Induction of cell apoptosis in vitro by Cyt D
A TUNEL-based assay that detects the amount of nickends generated as a result of DNA fragmentation during apoptosis was performed in a commercial Kit and the results were relatively compared to the negative control (as 1) (Figure 2 ). The amount of nick-ends in the CT26 cells treated with DMSO 
The optimum effective dose of Cyt D
In order to choose an optimum effective dose of Cyt D for use in the in vivo, CT26-bearing BABL/c mice were treated with Cyt D at different dose. Our results demonstrated that 12.5 to 100 mg/kg Cyt D showed in a pattern of dosedependent ( Figure 3) . The mice treated with 12.5 and 25 mg/kg Cyt D showed somewhat inhibition of tumor growth. However, the mice treated with 50 and 100 mg/kg have the best effects in suppression of tumor growth (Figure 3) . Thus, we selected the dose of 50 mg/kg as the optimum effective dose and used for subsequent in vivo experiments.
Inhibition of tumor growth by Cyt D
The antitumor activities of Cyt D were observed in vivo in CT26 tumor model. CT26-bearing BABL/c mice were treated with Cyt D and DMSO, respectively, and tumor volumes ( Figure 4A ) and survival time ( Figure 4B) were observed. Compared with the mice treated with DMSO, the mice treated with Cyt D were showed significant inhibition of tumor growth and prolong survival time (Figure 4 ). Both tumor volume and survival time were found significant differences at day 16 after CT26 tumor cell injection (Figure 4 , P < 0.01 or less). Thereafter, FITC-dextran in the beads was quantified (C). Data are expressed as means 依 SEM, * P < 0.001.
Discussion
Cytochalasins are mainly isolated from tropical symbiotic fungi in tropical plants. When they were first isolated, scientists were considered them as possible cytotoxic agents and tried to use in cancer therapy. Several lines of evidence have demonstrated that cytochalasins can act on cell and tissue morphology and function in vitro among normal and cancer cells [17] [18] [19] [20] [21] [22] . Cytochalasins can affect many cell fuctions, including adherence, cell motility, drug efflux, secretion, indicating that the cytochalasins might induce significant responses in experimental cancer chemotherapy model systems either as individual agents or, more likely, as agents amplifying responses induced by known antitumor drugs [14] . Up to now, many study results have indicated that cytochalasin D (Cyt D) is the most specific cytochalasins acting on the microfilaments. Thus, it is conceivable that Cyt D may potentially be a cytotoxic agent for cancer therapy. In this study, we used murine colorectal tumor cell line CT26 to investigate the possible Cyt D's anticancer activities in vitro and in vivo. Results from cell proliferation assay by MTT method showed that Cyt D inhibited CT26 cell proliferation in a dose and time dependent pattern, and the climax inhibition ratio reached almost at 80 percent.
A TUNEL-based assay to detect the CT26 cell apoptosis in vitro indicated that Cyt D had strong capabilities of inducing CT26 cell apoptosis, Cyt D (7.5 毺 g/mL) induced CT26 tumor cell apoptosis almost reaching the level induced by positive control nuclease. As we know, inhibition of tumor cell proliferation and induction of tumor cell apoptosis are two major mechanisms by which cytotoxic agents act on cancer cells. Chemotherapy, radiation therapy, and immunotherapy all rely heavily on inhibition of proliferation and apoptosis to kill cancer cells [23] [24] [25] . Thus, our in vitro results in the current study suggest that Cyt D is a excellent cytotoxic agent and has the potential prospects for using in cancer therapy.
Although As we know, the growth and persistence of solid tumors and their metastases depend majorly on angiogenesis [26, 27] . Therefore, anti-angiogenic therapy, which targets genetically stable endothelial cells, is also an optimal alternative for the treatment of tumors. Combination of these two strategies for tumor therapies has indicated a promising advantage in many previous preclinical studies [28] [29] [30] . The results in our current study showed that Cyt D could induce inhibition of CT26 tumor angiogenesis. Although our results in this study do not unveil the possible mechanism by which Cyt D acts on the tumor angiogenesis, many previous studies indicated that almost all cytotoxic agents clinically used for cancer therapy have the capabilities of inhibition of tumor angiogenesis even in small dose. Tumor angiogenesis is related to endothelial cells, which are active cells as cancer cells, cytotoxic agents thus can kill the endothelial cells in the same mechanisms. Our in vitro results indicated that Cyt D could inhibit CT26 cell proliferation and induce cell apoptosis; we thus consider that both inhibition of cell proliferation and promotion of cell apoptosis by Cyt D are involved in the processes of inhibiting tumor angiogenesis in vivo. However, the exact molecular mechanisms behind these phenomena induced by Cyt D remain unknown and need to be further investigated in the future.
Cyt D is a fungal metabolite that is capable of permeating cell membranes, binding to actin and altering its polymerization. At present, Cyt D is reported to be the most specific for the actin cytoskeleton among cytochalasins [13] . As we know, the Cyt D's targets, microfilaments, are ubiquitous in eukaryotic cells, if Cyt D is considered to be used as a cytotoxic agent, it will be possible to induce extensive side effects. In this study, although we found Cyt D is possible an effective cytotoxic agent for treatment of CT26 tumor, we did not perform experiments to investigate its side effects. Thus, detailed and systematic studies are need to be carried out to investigate the possible side effects when consider using Cyt D as an anticancer agent in the further.
In summary, we used murine colorectal tumor cell line CT26 to investigate the possible anticancer activities of Cyt D in vitro and in vivo. Our study results suggested that the Cyt D could effectively induce inhibition of CT26 tumor cell proliferation and cell apoptosis in vitro, and caused tumor suppression of CT26 tumor growth and angiogenesis in vivo. Thus, Cyt D may be potentially used as a cytotoxic agent for cancer therapy.
